Andrew Wagner, MD, Oncology, Boston, MA, South Shore Hospital

AndrewJWagnerMDPhD

Oncology Boston, MA

Sarcoma

Assistant Professor of Medicine, Dana-Farber Cancer Institute

Dr. Wagner is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Wagner's full profile

Already have an account?

Education & Training

  • Brigham and Women's Hospital
    Brigham and Women's HospitalFellowship, Hematology/Oncology, 2000 - 2005
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 1997 - 2000
  • University of Chicago Pritzker School of Medicine
    University of Chicago Pritzker School of MedicineClass of 1997

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1999 - 2022
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open l... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su)... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • Aadi Bioscience Breakthrough Therapy Nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComa
    Aadi Bioscience Breakthrough Therapy Nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComaNovember 14th, 2019
  • Aadi Bioscience Breakthrough Therapy Nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa
    Aadi Bioscience Breakthrough Therapy Nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComaJune 4th, 2019
  • Phase III Data on Eribulin in Advanced STS
    Phase III Data on Eribulin in Advanced STSJanuary 27th, 2016
  • Join now to see all

Professional Memberships

Hospital Affiliations